DOI: https://doi.org/10.14710/jbtr.v10i1.20338

The Influence of CYP2C19 Gene Polymorphism on Selective Serotonin Reuptake Inhibitors In Patients with Major Depressive Disorder: A Pharmacogenetic Prospecting Approach

1Department of Pharmacy, Faculty of Health Science, Universitas Singaperbangsa Karawang, Indonesia

2Department and Division of Practical Cosmetology and Skin Disease Prophylaxis, Poznan University of Medical Sciences, Indonesia

3Microbiology and Biotechnology Laboratory, Faculty of Pharmacy, Universitas Indonesia, Indonesia

4 Helix Laboratory and Clinic, Indonesia

5 Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Sumatera Utara, Indonesia

View all affiliations
Received: 22 Sep 2023; Accepted: 29 Apr 2024; Available online: 30 Apr 2024; Published: 30 Apr 2024.
Open Access Copyright (c) 2024 Journal of Biomedicine and Translational Research
Creative Commons License This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Citation Format:
Abstract

Major Depressive Disorder (MDD) is a chronic disorder characterized by at least a two-week-long major depressive episode. Selective Serotonin Reuptake Inhibitors (SSRIs) remain the primary prescribed antidepressants to treat MDD. However, SSRIs themselves are found to be ineffective in some individuals or may even lead to adverse side effects. These variable responses have been linked to the drug being metabolized by CYP2C19, which exhibited various polymorphisms. Understanding how gene polymorphism affects drug metabolism is essential since these insights can revolutionize clinical practice, allowing for more precise and personalized treatment approaches that optimize efficacy while minimizing side effects. This issue is particularly pertinent in Indonesia, where research in this area lags behind the pressing need for such studies. In this review, the impact of CYP2C19 polymorphism on the effectiveness of SSRI class drugs, namely citalopram, escitalopram, and sertraline, are explored. Nine relevant articles related to the topic have been studied in Japan, China, Turkey, Russia, Scandinavia, and Australia. The results concluded that CYP2C19 polymorphism can influence the metabolism of SSRIs (citalopram, escitalopram, and sertraline) due to its variability in enzyme activities, which includes both loss-of-function (*2, *3) and gain-of-function (*17) polymorphisms. Consequently, these genetic variations can lead to significant changes in drug efficacy and safety changes within individual patients. This review sheds light on the importance of considering genetic factors when prescribing SSRIs for MDD in the future treatment strategies.

Fulltext View|Download
Keywords: Major Depressive Disorder; CYP2C19; Gene Polymorphism; Selective Serotonin Reuptake Inhibitors; Drug Metabolism

Article Metrics:

Article Info
Section: Review Articles
Language : EN
Recent articles
Correlation Between Corrected TIMI Frame Count with the Extent of Myocardial Fibrosis on ST-Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention The Impact of Butterfly Pea Flower (Clitoria ternatea L.) Extract on Atherosclerosis Biomarker Profiles in Obese White Rats (Rattus norvegicus L.) Novel Endophytic Bacteria Isolates from Andaliman (Zancthoxylum acanthopodium DC.) which Potentially Inhibit Escherichia coli and Staphylococcus aureus Squamous Cell Carcinoma Cervical Uterine Metastasis in Abdominal Wall: A Rare Case Report The Influence of CYP2C19 Gene Polymorphism on Selective Serotonin Reuptake Inhibitors In Patients with Major Depressive Disorder: A Pharmacogenetic Prospecting Approach More recent articles
  1. Rose AL, Hopko DR, Lejuez CW, Magidson JF. Major Depressive Disorder. Functional Analysis in Clinical Treatment, Second Edition [Internet]. 2022 Jun 1 [cited 2023 Jun 4];339–73. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559078/ doi: 10.1016/B978-0-12-805469-7.00015-2
  2. Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al. Major depressive disorder. Nat Rev Dis Primers. 2016 Sep 15;2. doi: 10.1038/NRDP.2016.65
  3. Bernini de Brito R, Ghedini PC. CYP2C19 polymorphisms and outcomes of Escitalopram treatment in Brazilians with major depression. Heliyon. 2020 May;6(5):e04015. doi: 10.1016/j.heliyon.2020.e04015
  4. Campos AI, Byrne EM, Mitchell BL, Wray NR, Lind PA, Licinio J, et al. Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study. Pharmacogenomics J. 2022 Mar 29;22(2):130–5. doi: 10.1038/s41397-022-00267-7
  5. Chu A, Wadhwa R. Selective Serotonin Reuptake Inhibitors. 2023
  6. Fredman SJ, Fava M, Kienke AS, White CN, Nierenberg AA, Rosenbaum JF. Partial Response, Nonresponse, and Relapse With Selective Serotonin Reuptake Inhibitors in Major Depression. J Clin Psychiatry. 2000 Jun 15;61(6):403–8. doi: 10.4088/JCP.v61n0602
  7. Aldrich SL, Poweleit EA, Prows CA, Martin LJ, Strawn JR, Ramsey LB. Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders. Front Pharmacol. 2019 Feb 19;10. doi: 10.3389/fphar.2019.00099
  8. Dorji PW, Tshering G, Na‐Bangchang K. CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South‐East and East Asian populations: A systematic review. J Clin Pharm Ther. 2019 Apr 13;jcpt.12835. doi: 10.1111/jcpt.12835
  9. Eugene AR. Optimizing drug selection in psychopharmacology based on 40 significant CYP2C19- and CYP2D6-biased adverse drug reactions of selective serotonin reuptake inhibitors. PeerJ [Internet]. 2019 [cited 2023 Jun 4];7(10). Available from: /pmc/articles/PMC6790106/ doi: 10.7717/PEERJ.7860
  10. Petry N, Lupu R, Gohar A, Larson EA, Peterson C, Williams V, et al. CYP2C19 genotype, physician prescribing pattern, and risk for long QT on serotonin selective reuptake inhibitors. Pharmacogenomics [Internet]. 2019 Apr 1 [cited 2023 Jun 4];20(5):343. Available from: /pmc/articles/PMC6562837/ doi: 10.2217/PGS-2018-0156
  11. Chang M, Tybring G, Dahl ML, Lindh JD. Impact of Cytochrome P450 2C19 Polymorphisms on Citalopram/Escitalopram Exposure: A Systematic Review and Meta-Analysis. Clin Pharmacokinet. 2014 Sep 26;53(9):801–11. doi: 10.1007/s40262-014-0162-1
  12. Sangkuhl K, Klein TE, Altman RB. PharmGKB summary. Pharmacogenet Genomics. 2011 Nov;21(11):769–72. doi: 10.1097/FPC.0b013e328346063f
  13. Kobayashi K, Ishizuka T, Shimada N, Yoshimura Y, Kamijima K, Chiba K. Sertraline N-Demethylation Is Catalyzed by Multiple Isoforms of Human Cytochrome P-450 In Vitro. Drug Metabolism and Disposition. 1999;27(7)
  14. Xu ZH, Wang W, Zhao XJ, Huang SL, Zhu B, He N, et al. Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes. Br J Clin Pharmacol [Internet]. 1999 Sep 1 [cited 2023 Jun 4];48(3):416–23. Available from: https://onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2125.1999.00023.x
  15. Huddart R, Hicks JK, Ramsey LB, Strawn JR, Smith DM, Bobonis Babilonia M, et al. PharmGKB summary: sertraline pathway, pharmacokinetics. Pharmacogenet Genomics. 2020 Feb;30(2):26–33. doi: 10.1097/FPC.0000000000000392
  16. Gurusamy U, Shewade DG. Pharmacogenomics in India. In: Handbook of Pharmacogenomics and Stratified Medicine. Elsevier; 2014. p. 1037–59. doi: 10.1016/B978-0-12-386882-4.00046-3
  17. Díaz-Ordóñez L, Ramírez-Montaño D, Candelo E, González-Restrepo C, Silva-Peña S, Rojas CA, et al. Evaluation of CYP2C19 Gene Polymorphisms in Patients with Acid Peptic Disorders Treated with Esomeprazole. Pharmgenomics Pers Med [Internet]. 2021 [cited 2023 Jun 4];14:509. Available from: /pmc/articles/PMC8092628/ doi: 10.2147/PGPM.S285144
  18. Jukić MM, Haslemo T, Molden E, Ingelman-Sundberg M. Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients. American Journal of Psychiatry. 2018 May;175(5):463–70. doi: 10.1176/appi.ajp.2017.17050550
  19. Huang X, Li C, Li C, Li Z, Li X, Liao J, et al. CYP2C19 Genotyping May Provide a Better Treatment Strategy when Administering Escitalopram in Chinese Population. Front Pharmacol. 2021 Aug 27;12. doi: 10.3389/fphar.2021.730461
  20. Tsuchimine S, Ochi S, Tajiri M, Suzuki Y, Sugawara N, Inoue Y, et al. Effects of Cytochrome P450 (CYP) 2C19 Genotypes on Steady-State Plasma Concentrations of Escitalopram and its Desmethyl Metabolite in Japanese Patients With Depression. Ther Drug Monit. 2018 Jun;40(3):356–61. doi: 10.1097/FTD.0000000000000506
  21. Uckun Z, Baskak B, Ozel-Kizil ET, Ozdemir H, Devrimci Ozguven H, Suzen HS. The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder. J Clin Pharm Ther. 2015 Dec;40(6):672–9. doi: 10.1111/jcpt.12320
  22. Zastrozhin MS, Skryabin VY, Petukhov AE, Torrado M V., Pankratenko EP, Zastrozhina AK, et al. Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder. Pharmacogenomics J. 2021 Aug 19;21(4):435–9. doi: 10.1038/s41397-021-00219-7
  23. Yuce-Artun N, Baskak B, Ozel-Kizil ET, Ozdemir H, Uckun Z, Devrimci-Ozguven H, et al. Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients. Int J Clin Pharm. 2016 Apr 30;38(2):388–94. doi: 10.1007/s11096-016-0259-8
  24. Westbrook K, Stearns V. Pharmacogenomics of breast cancer therapy: An update. Pharmacol Ther. 2013 Jul;139(1):1–11. doi: 10.1016/j.pharmthera.2013.03.001
  25. Chan CWH, Law BMH, So WKW, Chow KM, Waye MMY. Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen. J Cancer Res Clin Oncol. 2020 Jun 8;146(6):1395–404. doi: 10.1007/s00432-020-03206-w
  26. Cho SH. Pharmacogenomic Approaches to Asthma Treatment. Allergy Asthma Immunol Res. 2010;2(3):177. doi: 10.4168/aair.2010.2.3.177
  27. Bousman CA, Arandjelovic K, Mancuso SG, Eyre HA, Dunlop BW. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics. 2019 Jan;20(1):37–47. doi: 10.2217/pgs-2018-0142
  28. Aboelbaha S, Zolezzi M, Elewa H. Effect of Pharmacogenetic-Based Decision Support Tools in Improving Depression Outcomes: A Systematic Review. Neuropsychiatr Dis Treat. 2021 Jul;Volume 17:2397–419. doi: 10.2147/NDT.S312966
  29. Ikawati Z, Askitosari T, Hakim L, Tucci J, Mitchell J. Allele Frequency Distributions of the Drug Metabolizer Genes CYP2C9*2, CYP2C9*3, and CYP2C19*17 in the Buginese Population of Indonesia. Curr Pharmacogenomics Person Med. 2015 Jun 11;12(4):236–9. doi: 10.2174/1875692113666150410214416
  30. Miftahussurur M, Doohan D, Syam AF, Nusi IA, Subsomwong P, Waskito LA, et al. CYP2C19 Polymorphisms in Indonesia: Comparison among Ethnicities and the Association with Clinical Outcomes. Biology (Basel). 2021 Apr 6;10(4):300. doi: 10.3390/biology10040300
  31. Bråten LS, Haslemo T, Jukic MM, Ingelman-Sundberg M, Molden E, Kringen MK. Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients. Neuropsychopharmacology. 2020 Feb 24;45(3):570–6. doi: 10.1038/s41386-019-0554-x

Last update:

No citation recorded.

Last update:

No citation recorded.